Cargando…
Obesity and Erectile Dysfunction: From Bench to Clinical Implication
Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both conditions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and l...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Sexual Medicine and Andrology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479091/ https://www.ncbi.nlm.nih.gov/pubmed/30079640 http://dx.doi.org/10.5534/wjmh.180026 |
_version_ | 1783413274833846272 |
---|---|
author | Moon, Ki Hak Park, So Young Kim, Yong Woon |
author_facet | Moon, Ki Hak Park, So Young Kim, Yong Woon |
author_sort | Moon, Ki Hak |
collection | PubMed |
description | Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both conditions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and leptin resistance. Moreover, the severity of ED is correlated with comorbid medical conditions, including obesity. Therefore, amelioration of these comorbidities may increase the efficacy of ED treatment with phosphodiesterase 5 inhibitors, the first-line medication for patients with ED. Although metformin was originally developed as an insulin sensitizer six decades ago, it has also been shown to improve leptin resistance. In addition, metformin has been reported to reduce oxidative stress, inflammatory response, and body weight, as well as improve ED, in animal and human studies. Moreover, administration of a combination of metformin and phosphodiesterase 5 inhibitors improves erectile function in patients with ED who have a poor response to sildenafil and are insulin resistant. Thus, concomitant treatment of metabolic derangements associated with obesity in patients with ED who are obese would improve the efficacy and reduce the refractory response to penile vasodilators. In this review, we discuss the connecting factors between obesity and ED and the possible combined treatment modalities. |
format | Online Article Text |
id | pubmed-6479091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Society for Sexual Medicine and Andrology |
record_format | MEDLINE/PubMed |
spelling | pubmed-64790912019-05-08 Obesity and Erectile Dysfunction: From Bench to Clinical Implication Moon, Ki Hak Park, So Young Kim, Yong Woon World J Mens Health Review Article Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both conditions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and leptin resistance. Moreover, the severity of ED is correlated with comorbid medical conditions, including obesity. Therefore, amelioration of these comorbidities may increase the efficacy of ED treatment with phosphodiesterase 5 inhibitors, the first-line medication for patients with ED. Although metformin was originally developed as an insulin sensitizer six decades ago, it has also been shown to improve leptin resistance. In addition, metformin has been reported to reduce oxidative stress, inflammatory response, and body weight, as well as improve ED, in animal and human studies. Moreover, administration of a combination of metformin and phosphodiesterase 5 inhibitors improves erectile function in patients with ED who have a poor response to sildenafil and are insulin resistant. Thus, concomitant treatment of metabolic derangements associated with obesity in patients with ED who are obese would improve the efficacy and reduce the refractory response to penile vasodilators. In this review, we discuss the connecting factors between obesity and ED and the possible combined treatment modalities. Korean Society for Sexual Medicine and Andrology 2019-05 2018-07-25 /pmc/articles/PMC6479091/ /pubmed/30079640 http://dx.doi.org/10.5534/wjmh.180026 Text en Copyright © 2019 Korean Society for Sexual Medicine and Andrology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Moon, Ki Hak Park, So Young Kim, Yong Woon Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title | Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_full | Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_fullStr | Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_full_unstemmed | Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_short | Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_sort | obesity and erectile dysfunction: from bench to clinical implication |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479091/ https://www.ncbi.nlm.nih.gov/pubmed/30079640 http://dx.doi.org/10.5534/wjmh.180026 |
work_keys_str_mv | AT moonkihak obesityanderectiledysfunctionfrombenchtoclinicalimplication AT parksoyoung obesityanderectiledysfunctionfrombenchtoclinicalimplication AT kimyongwoon obesityanderectiledysfunctionfrombenchtoclinicalimplication |